表紙
市場調查報告書
商品編碼
865032

免疫性血小板減少性疾病治療藥的全球市場:2019年∼2023年

Global Immune Thrombocytopenia Drugs Market 2019-2023

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 136 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

免疫性血小板減少症在年輕女性中很常見,並且其患有類風濕性關節炎、HIV、肝炎、狼瘡和抗磷脂症候群等疾病的風險更高。這些疾病的患病率在世界範圍內很高。例如,在2016年,美國有超過一百萬人被診斷出患有艾滋病毒感染,而美國近1%的成年人患有C型肝炎。此類風險因素的發病率不斷增加將增加免疫性血小板減少症的患病率。這將增加對治療選擇的需求,從而在預測期間推動全球免疫性血小板減少症市場規模的成長,年複合成長率預計將接近5%。

本報告提供全球免疫性血小板減少性疾病治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • TPO-Ras
  • 皮質類固醇
  • IVIG
  • 其他
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 特別的法規的指定
  • 意識提升計劃的增加
  • 生物相似藥的開發

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Amgen Inc.
  • CSL Ltd.
  • Horizon Therapeutics Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Rigel Pharmaceuticals Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31389

About this market

Immune thrombocytopenia is common among young women, and its risk is higher in people with diseases such as rheumatoid arthritis, HIV, hepatitis, lupus, and antiphospholipid syndrome. The prevalence of these diseases is high across the world. For instance, in 2016, over a million people in the US were diagnosed with HIV infection, and nearly 1% of the adults in the US had Hepatitis C. The growing incidences of such risk factors will increase the prevalence of immune thrombocytopenia. This will increase the demand for treatment options, thereby driving the growth of the global immune thrombocytopenia market size at a CAGR of nearly 5% during the forecast period.

Market Overview

Expected approvals for late-stage pipeline molecules

The market is witnessing accelerated growth in the number of molecules in the pipeline for the treatment of immune thrombocytopenia. At present, there are over 5 therapeutics to treat immune thrombocytopenia. These drugs are in the late stages of development and are slated to receive marketing approvals during the forecast period.

Availability of substitutes

The side effects associated with the available drugs for the treatment of immune thrombocytopenia are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global immune thrombocytopenia market size.

For the detailed list of factors that will drive and challenge the growth of the immune thrombocytopenia market size during 2019-2023.

Competitive Landscape

The market appears to be fragmented with several players occupying the market share. Companies such as Amgen Inc. and CSL Ltd. Have intensified the competition. Factors such as the high prevalence of associated risk factors for immune thrombocytopenia and the expected approvals of late-stage pipeline molecules will provide significant growth opportunities for immune thrombocytopenia drug manufacturers. Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc. are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • TPO-Ras - Market size and forecast 2018-2023
  • Corticosteroids - Market size and forecast 2018-2023
  • IVIGs - Market size and forecast 2018-2023
  • Other drugs - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Special regulatory designations
  • Increasing number of awareness programs
  • Development of biosimilars

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • CSL Ltd.
  • Horizon Therapeutics Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Rigel Pharmaceuticals Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global hematology drugs market
  • Exhibit 02: Segments of global hematology drugs market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: TPO-Ras - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Approved TPO-Ras
  • Exhibit 21: Pipeline of TPO-Ras
  • Exhibit 22: TPO-Ras - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Some of the generic sponsors for corticosteroids
  • Exhibit 25: Corticosteroids - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: IVIGs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Some of the available IVIGs
  • Exhibit 28: Side effects of IVIGs
  • Exhibit 29: Approximate Costs of IVIGs
  • Exhibit 30: IVIGs - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Other drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Off-label drugs for immune thrombocytopenia
  • Exhibit 33: Other drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Market opportunity by product
  • Exhibit 35: Customer landscape
  • Exhibit 36: Market share by geography 2018-2023 (%)
  • Exhibit 37: Geographic comparison
  • Exhibit 38: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in North America
  • Exhibit 41: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Top 3 countries in Europe
  • Exhibit 44: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 45: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 46: Top 3 countries in Asia
  • Exhibit 47: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 48: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 49: Top 3 countries in ROW
  • Exhibit 50: Key leading countries
  • Exhibit 51: Market opportunity
  • Exhibit 52: Prevalence of associated risk factors for immune thrombocytopenia
  • Exhibit 53: Drug development pipeline for immune thrombocytopenia
  • Exhibit 54: Side effects associated with available drugs
  • Exhibit 55: Alternative therapies for immune thrombocytopenia
  • Exhibit 56: Impact of drivers and challenges
  • Exhibit 57: Drug designations
  • Exhibit 58: Vendor landscape
  • Exhibit 59: Landscape disruption
  • Exhibit 60: Vendors covered
  • Exhibit 61: Vendor classification
  • Exhibit 62: Market positioning of vendors
  • Exhibit 63: Amgen Inc. - Vendor overview
  • Exhibit 64: Amgen Inc. - Business segments
  • Exhibit 65: Amgen Inc. - Organizational developments
  • Exhibit 66: Amgen Inc. - Geographic focus
  • Exhibit 67: Amgen Inc. - Key offerings
  • Exhibit 68: Amgen Inc. - Key customers
  • Exhibit 69: CSL Ltd. - Vendor overview
  • Exhibit 70: CSL Ltd. - Business segments
  • Exhibit 71: CSL Ltd. - Organizational developments
  • Exhibit 72: CSL Ltd. - Geographic focus
  • Exhibit 73: CSL Ltd. - Segment focus
  • Exhibit 74: CSL Ltd. - Key offerings
  • Exhibit 75: CSL Ltd. - Key customers
  • Exhibit 76: Horizon Therapeutics Plc - Vendor overview
  • Exhibit 77: Horizon Therapeutics Plc - Business segments
  • Exhibit 78: Horizon Therapeutics Plc - Organizational developments
  • Exhibit 79: Horizon Therapeutics Plc - Geographic focus
  • Exhibit 80: Horizon Therapeutics Plc - Segment focus
  • Exhibit 81: Horizon Therapeutics Plc - Key offerings
  • Exhibit 82: Horizon Therapeutics Plc - Key customers
  • Exhibit 83: Merck & Co. Inc. - Vendor overview
  • Exhibit 84: Merck & Co. Inc. - Business segments
  • Exhibit 85: Merck & Co. Inc. - Organizational developments
  • Exhibit 86: Merck & Co. Inc. - Geographic focus
  • Exhibit 87: Merck & Co. Inc. - Segment focus
  • Exhibit 88: Merck & Co. Inc. - Key offerings
  • Exhibit 89: Merck & Co. Inc. - Key customers
  • Exhibit 90: Novartis AG - Vendor overview
  • Exhibit 91: Novartis AG - Business segments
  • Exhibit 92: Novartis AG - Organizational developments
  • Exhibit 93: Novartis AG - Geographic focus
  • Exhibit 94: Novartis AG - Segment focus
  • Exhibit 95: Novartis AG - Key offerings
  • Exhibit 96: Novartis AG - Key customers
  • Exhibit 97: Rigel Pharmaceuticals Inc. - Vendor overview
  • Exhibit 98: Rigel Pharmaceuticals Inc. - Business segments
  • Exhibit 99: Rigel Pharmaceuticals Inc. - Organizational developments
  • Exhibit 100: Rigel Pharmaceuticals Inc. - Key offerings
  • Exhibit 101: Rigel Pharmaceuticals Inc. - Key customers
  • Exhibit 102: Validation techniques employed for market sizing
  • Exhibit 103: Definition of market positioning of vendors